Nuclear receptors, such as the glucocorticoid receptor (GR), the retinoid x receptors (RXR), the peroxisomal proliferator‐activated receptor α (PPARα), and gamma (PPARγ), are targets of already approved drugs for the treatment of autoimmunity, cancer, hyperlipidemia, or type 2 diabetes [12]. The gene discussed is NR3C1; the disease is hyperlipidemia.